Gonadal steroids and opioid control of gonadotropin secretion in man

Fertil Steril. 1983 Dec;40(6):798-801. doi: 10.1016/s0015-0282(16)47482-0.

Abstract

The aim of this study was to ascertain whether there was an interrelationship between gonadal steroids and endogenous opioid peptides. The effects of naloxone (20 mg, intravenously) and of a met-enkephalin analog (DAMME) (250 micrograms, intravenously) on gonadotropin secretion in three castrated men (18 to 23 years of age) and in five age-matched normal men were studied. Normal subjects were studied before and after treatment with a specific nonsteroidal estrogen receptor antagonist, clomiphene. Naloxone caused a significant increase in luteinizing hormone (LH) (P less than 0.05); in these subjects, clomiphene treatment significantly increased LH and follicle-stimulating hormone plasma levels but totally suppressed the naloxone-induced rise in LH. In castrated men, naloxone failed to increase plasma LH levels. However, DAMME significantly reduced plasma LH levels in normal, in castrated, and in clomiphene-treated normal subjects. The results demonstrate that in castrated subjects who lack gonadal steroids and in normal subjects with blocked estrogen receptors there is a reduced opioid inhibitory tone on gonadotropin secretion. The effect of DAMME on gonadotropin secretion, however, is not influenced by the gonadal steroid environment.

MeSH terms

  • Adolescent
  • Adult
  • Castration
  • Clomiphene / pharmacology
  • D-Ala(2),MePhe(4),Met(0)-ol-enkephalin / pharmacology*
  • Follicle Stimulating Hormone / metabolism*
  • Humans
  • Luteinizing Hormone / metabolism*
  • Male
  • Naloxone / pharmacology
  • Receptors, Opioid / physiology*

Substances

  • Receptors, Opioid
  • Clomiphene
  • Naloxone
  • D-Ala(2),MePhe(4),Met(0)-ol-enkephalin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone